Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02 · 8-K

Corvus Pharmaceuticals, Inc.

CRVSNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), effective as of July 22, 2026. The Company thanks Mr.…

Filed Jul 22, 2026Accepted Jul 22, 2026, 4:02 PM EDTCIK 1626971Accession 0001104659-26-085790
Share

Company context

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

Current securities

Recent company filings

  1. 10-Q filingNov 5, 2026
  2. Results of Operations and Financial ConditionNov 5, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. 4 filingJun 15, 2026

Registered securities in this filing

Corvus Pharmaceuticals, Inc. · 8-K · Filed 2026-07-22

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $0.0001 per share

Symbol
CRVS
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Duration_7_21_2026_To_7_21_2026_CM3l0sAHIkmk-cF_fwX_Jg

Dimensions: Not supplied

Accession 000110465926085790 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), effective as of July 22, 2026. The Company thanks Mr. Clark for his significant contributions to the Company during over nine years of Board service.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.